Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: A systematic review

British Journal of Haematology

Volumn 162, Issue 1, 2013, Pages 50-61

  Regelink, Josien C ^a   Minnema, Monique C ^b   Terpos, Evangelos ^c   Kamphuis, Marjolein H ^b   Raijmakers, Pieter G ^a   Pieters van den Bos, Indra C ^a   Heggelman, Ben G F ^d   Nievelstein, Rutger Jan ^b   Otten, Rene H J ^e   van Lammeren Venema, Danielle ^f   Zijlstra, Josee M ^a   Arens, Anne I J ^g   de Rooy, Jacky W ^g   Hoekstra, Otto S ^a   Raymakers, Reinier ^b   Sonneveld, Pieter ^h   Ostelo, Raymond W ^a   Zweegman, Sonja ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d MEANDER MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

^f HAGA HOSPITAL   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bone disease; Magnetic resonance imaging; Multiple myeloma; Positron emission tomography computerized tomography; X ray

Indexed keywords

ARTICLE; BONE DISEASE; CANCER PROGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; WHOLE BODY CT;

BONE DISEASES; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84879099692     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12346     Document Type: Article

References (50)

1. Adam, Z., Bolcak, K., Stanicek, J., Buchler, T., Pour, L., Krejci, M., Prasek, J., Neubauer, J., Vorlicek, J. & Hajek, R. (2007) Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance. Neoplasma, 54, 536-540.
2. Agren, B., Rudberg, U., Isberg, B., Svensson, L. & Aspelin, P. (1998) MR imaging of multiple myeloma patients with bone-marrow transplants. Acta radiologica (Stockholm, Sweden: 1987), 39, 36-42.
3. Bartel, T.B., Haessler, J., Brown, T.L.Y., Shaughnessy, J.D.J., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., Crowley, J. & Barlogie, B. (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood, 114, 2068-2076.
4. Baur, A., Stabler, A., Nagel, D., Lamerz, R., Bartl, R., Hiller, E., Wendtner, C., Bachner, F. & Reiser, M. (2002) Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer, 95, 1334-1345.
5. Baur-Melnyk, A., Buhmann, S., Becker, C., Schoenberg, S.O., Lang, N., Bartl, R. & Reiser, M.F. (2008) Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR American Journal of Roentgenology, 190, 1097-1104.
6. Bredella, M.A., Steinbach, L., Caputo, G., Segall, G. & Hawkins, R. (2005) Value of FDG PET in the assessment of patients with multiple myeloma. AJR American Journal of Roentgenology, 184, 1199-1204.
7. Breyer, R.J., Mulligan, M.E., Smith, S.E., Line, B.R. & Badros, A.Z. (2006) Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiology, 35, 632-640.
8. Dimopoulos, M.A., Moulopoulos, A., Smith, T., Delasalle, K.B. & Alexanian, R. (1993) Risk of disease progression in asymptomatic multiple myeloma. American Journal of Medicine, 94, 57-61.
9. Dimopoulos, M., Terpos, E., Comenzo, R.L., Tosi, P., Beksac, M., Sezer, O., Siegel, D., Lokhorst, H., Kumar, S., Rajkumar, S.V., Niesvizky, R., Moulopoulos, L.A. & Durie, B.G.M. (2009) International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 23, 1545-1556.
10. Dinter, D.J., Neff, W.K., Klaus, J., Bohm, C., Hastka, J., Weiss, C., Schoenberg, S.O. & Metzgeroth, G. (2009) Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy. Annals of Hematology, 88, 457-464.
11. Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-854.
12. Durie, B.G.M., Waxman, A.D., D'Agnolo, A. & Williams, C.M. (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. Journal of Nuclear Medicine, 43, 1457-1463.
13. Fechtner, K., Hillengass, J., Delorme, S., Heiss, C., Neben, K., Goldschmidt, H., Kauczor, H.U. & Weber, M.A. (2010) Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology, 257, 195-204.
14. Fruehwald, F.X., Tscholakoff, D., Schwaighofer, B., Wicke, L., Neuhold, A., Ludwig, H. & Hajek, P.C. (1988) Magnetic resonance imaging of the lower vertebral column in patients with multiple myeloma. Investigative Radiology, 23, 193-199.
15. Ghanem, N., Lohrmann, C., Engelhardt, M., Pache, G., Uhl, M., Saueressig, U., Kotter, E. & Langer, M. (2006) Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. European Radiology, 16, 1005-1014.
16. Gleeson, T.G., Moriarty, J., Shortt, C.P., Gleeson, J.P., Fitzpatrick, P., Byrne, B., McHugh, J., O'Connell, M., O'Gorman, P. & Eustace, S.J. (2009) Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiology, 38, 225-236.
17. Haznedar, R., Aki, S., Akdemir, O., Ozkurt, Z., Ceneli, O., Yagci, M., Sucak, G. & Unlu, M. (2011) Value of (18)F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging, 38, 1046-1053.
18. Hillengass, J., Fechtner, K., Weber, M.A., Bauerle, T., Ayyaz, S., Heiss, C., Hielscher, T., Moehler, T.M., Egerer, G., Neben, K., Ho, A.D., Kauczor, H.U., Delorme, S. & Goldschmidt, H. (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. Journal of Clinical Oncology, 28, 1606-1610.
19. Hung, G.U., Tsai, C.C., Tsai, S.C. & Lin, W.Y. (2005) Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma. Anticancer Research, 25, 4737-4741.
20. Hur, J., Yoon, C.S., Ryu, Y.H., Yun, M.J. & Suh, J.S. (2007) Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography. Journal of Computer Assisted Tomography, 31, 342-347.
21. International Myeloma Working Group. (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757.
22. Joshi, U., Raijmakers, P.G., Riphagen, I.I., Teule, G.J., Van, L.A. & Hoekstra, O.S. (2007) Attenuation-corrected vs. nonattenuation-corrected 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in oncology: a systematic review. Molecular Imaging Biology, 9, 99-105.
23. Kusumoto, S., Jinnai, I., Itoh, K., Kawai, N., Sakata, T., Matsuda, A., Tominaga, K., Murohashi, I., Bessho, M., Harashima, K. & Heshiki, A. (1997) Magnetic resonance imaging patterns in patients with multiple myeloma. British Journal of Haematology, 99, 649-655.
24. Laroche, M., Assoun, J., Sixou, L. & Attal, M. (1996) Comparison of MRI and computed tomography in the various stages of plasma cell disorders: correlations with biological and histological findings Myelome-Midi-Pyrenees Group. Clinical and Experimental Rheumatology, 14, 171-176.
25. Lecouvet, F.E., Van de Berg, B.C., Michaux, L., Malghem, J., Maldague, B.E., Jamart, J., Ferrant, A. & Michaux, J.L. (1998) Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology, 209, 653-660.
26. Lecouvet, F.E., Malghem, J., Michaux, L., Maldague, B., Ferrant, A., Michaux, J.L. & Van de Berg, B.C. (1999) Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. British Journal of Haematology, 106, 35-39.
27. Ludwig, H., Fruhwald, F., Tscholakoff, D., Rasoul, S., Neuhold, A. & Fritz, E. (1987) Magnetic resonance imaging of the spine in multiple myeloma. Lancet, 2, 364-366.
28. Mahnken, A.H., Wildberger, J.E., Gehbauer, G., Schmitz-Rode, T., Blaum, M., Fabry, U. & Gunther, R.W. (2002) Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR American Journal of Roentgenology, 178, 1429-1436.
29. Mariette, X., Zagdanski, A.M., Guermazi, A., Bergot, C., Arnould, A., Frija, J., Brouet, J.C. & Fermand, J.P. (1999) Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. British Journal of Haematology, 104, 723-729.
30. Mateos, M.V., López-Corral, l., Hernández, M., Giraldo, P., De La Rubia, J., De Arriba, F., Rosiñol, L., Lahuerta, J.J., Palomera, L., Bargay, J., Oriol, A., Prosper, F., López, J., Olavarría, E., Luz Martino, M., Teruel, A-I., Hernández, J.M., Esteves, G., Mariz Jmjs Leal-da-Costa, F., Alegre, A., Guzman, J-L., López de la Guía, A., Baquero, J., Quintana, N., García, J.L. & San Miguel, J.F. (2011) Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on lenalidomide-dexamethasone (len-dex) as induction therapy followed by maintenance therapy with len alone vs no treatment. Blood (ASH Annual Meeting Abstracts), 118, 991.
31. Moineuse, C., Kany, M., Fourcade, D., Aziza, R., Attal, M., Mazieres, B. & Laroche, M. (2001) Magnetic resonance imaging findings in multiple myeloma: description and predictive value. Joint Bone Spine, 68, 334-344.
32. Moulopoulos, L.A., Dimopoulos, M.A., Weber, D., Fuller, L., Libshitz, H.I. & Alexanian, R. (1993) Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. Journal of Clinical Oncology, 11, 1311-1315.
33. Moulopoulos, L.A., Dimopoulos, M.A., Smith, T.L., Weber, D.M., Delasalle, K.B., Libshitz, H.I. & Alexanian, R. (1995) Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. Journal of Clinical Oncology, 13, 251-256.
34. Moulopoulos, L.A., Gika, D., Anagnostopoulos, A., Delasalle, K., Weber, D., Alexanian, R. & Dimopoulos, M.A. (2005) Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Annals of Oncology, 16, 1824-1828.
35. Moulopoulos, L.A., Dimopoulos, M.A., Christoulas, D., Kastritis, E., Anagnostou, D., Koureas, A., Roussou, M., Gavriatopoulou, M., Migkou, M., Iakovaki, M., Gkotzamanidou, M., Tasidou, A. & Terpos, E. (2010) Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia, 24, 1206-1212.
36. Nanni, C., Zamagni, E., Farsad, M., Castellucci, P., Tosi, P., Cangini, D., Salizzoni, E., Canini, R., Cavo, M. & Fanti, S. (2006) Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 33, 525-531.
37. Nanni, C., Rubello, D., Zamagni, E., Castellucci, P., Ambrosini, V., Montini, G., Cavo, M., Lodi, F., Pettinato, C., Grassetto, G., Franchi, R., Gross, M.D. & Fanti, S. (2008) 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In vivo (Athens, Greece), 22, 513-517.
38. Schirrmeister, H., Bommer, M., Buck, A.K., Muller, S., Messer, P., Bunjes, D., Dohner, H., Bergmann, L. & Reske, S.N. (2002) Initial results in the assessment of multiple myeloma using 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 29, 361-366.
39. Schirrmeister, H., Buck, A.K., Bergmann, L., Reske, S.N. & Bommer, M. (2003) Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biotherapy and Radiopharmaceuticals, 18, 841-845.
40. Schreiman, J.S., McLeod, R.A., Kyle, R.A. & Beabout, J.W. (1985) Multiple myeloma: evaluation by CT. Radiology, 154, 483-486.
41. Spira, D., Weisel, K., Brodoefel, H., Schulze, M., Kaufmann, S. & Horger, M. (2012) Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)? Academic Radiology, 19, 89-94.
42. Tertti, R., Alanen, A. & Remes, K. (1995) The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine. British Journal of Haematology, 91, 658-660.
43. Van de Berg, B.C., Lecouvet, F.E., Michaux, L., Labaisse, M., Malghem, J., Jamart, J., Maldague, B.E., Ferrant, A. & Michaux, J.L. (1996) Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis. Radiology, 201, 243-246.
44. Van de Berg, B.C., Michaux, L., Lecouvet, F.E., Labaisse, M., Malghem, J., Jamart, J., Maldague, B.E., Ferrant, A. & Michaux, J.L. (1997) Nonmyelomatous monoclonal gammopathy: correlation of bone marrow MR images with laboratory findings and spontaneous clinical outcome. Radiology, 202, 247-251.
45. Walker, R., Barlogie, B., Haessler, J., Tricot, G., Anaissie, E., Shaughnessy, J.D.J., Epstein, J., van Hemert, R., Erdem, E., Hoering, A., Crowley, J., Ferris, E., Hollmig, K., van Rhee, F., Zangari, M., Pineda-Roman, M., Mohiuddin, A., Yaccoby, S., Sawyer, J. & Angtuaco, E.J. (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. Journal of Clinical Oncology, 25, 1121-1128.
46. Walker, R.C., Brown, T.L., Jones-Jackson, L.B., De, B.L. & Bartel, T. (2012) Imaging of multiple myeloma and related plasma cell dyscrasias. Journal of Nuclear Medicine, 53, 1091-1101.
47. Whiting, P., Rutjes, A.W., Reitsma, J.B., Bossuyt, P.M. & Kleijnen, J. (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Research Methodology, 3, 25.
48. Zamagni, E. & Cavo, M. (2012) The role of imaging techniques in the management of multiple myeloma. British Journal of Haematology, 159, 499-513.
49. Zamagni, E., Nanni, C., Patriarca, F., Englaro, E., Castellucci, P., Geatti, O., Tosi, P., Tacchetti, P., Cangini, D., Perrone, G., Ceccolini, M., Brioli, A., Buttignol, S., Fanin, R., Salizzoni, E., Baccarani, M., Fanti, S. & Cavo, M. (2007) A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica, 92, 50-55.
50. Zamagni, E., Patriarca, F., Nanni, C., Zannetti, B., Englaro, E., Pezzi, A., Tacchetti, P., Buttignol, S., Perrone, G., Brioli, A., Pantani, L., Terragna, C., Carobolante, F., Baccarani, M., Fanin, R., Fanti, S. & Cavo, M. (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood, 118, 5989-5995.